Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin May 8, 2023 Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress Read More »
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data Portfolio News / By Karina Tin May 4, 2023 NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data Read More »
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting Portfolio News / By Karina Tin May 3, 2023 Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting Read More »
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 Portfolio News / By Karina Tin May 2, 2023 Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 Read More »
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting Portfolio News / By Karina Tin April 24, 2023 Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting Read More »
Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting Portfolio News / By Karina Tin April 19, 2023 Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting Read More »
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting Portfolio News / By Karina Tin April 18, 2023 ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting Read More »
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations Portfolio News / By Karina Tin April 17, 2023 Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations Read More »
o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) Portfolio News / By Karina Tin April 16, 2023 o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) Read More »
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 Portfolio News / By Karina Tin April 16, 2023 Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 Read More »
